Stephen Begbie - Port Macquarie Base Hospital

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 45 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Pembrolizumab Plus Olaparib for Patients with Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: the Randomized, Open-Label, Phase III KEYLYNK-010 Trial

Emmanuel S. Antonarakis,Se Hoon Park,Jeffrey C. Goh,Sang Joon Shin, Jae Lyun Lee,Niven Mehra,Ray McDermott, Nuria Sala-Gonzalez,Peter C. Fong,Richard Greil,Margitta Retz,Juan Pablo Sade, Patricio Yanez, Yi-Hsiu Huang,Stephen D. Begbie,Rustem Airatovich Gafanov, Maria De Santis,Eli Rosenbaum,Michael P. Kolinsky,Felipe Rey, Kun-Yuan Chiu, Guilhem Roubaud,Gero Kramer, Makoto Sumitomo, Francesco Massari,Hiroyoshi Suzuki, Ping Qiu,Jinchun Zhang,Jeri Kim,Christian H. Poehlein,Evan Y. Yu

JOURNAL OF CLINICAL ONCOLOGY（2023）

Cited3Views0WOSBibtex

1362MO Pembrolizumab + Olaparib Vs Abiraterone (abi) or Enzalutamide (enza) for Patients (pts) with Previously Treated Metastatic Castration-Resistant Prostate Cancer (mcrpc): Randomized Open-Label Phase III KEYLYNK-010 Study

E.Y. Yu, S.H. Park,J.C.H. Goh, S.J. Shin, N. Mehra,R. McDermott, M.A. Sala Gonzalez,P.C. Fong, R. Greil,M. Retz, J.P. Sade,Y-H. Huang,S. Begbie, F. Rey,G. Kramer, H. Suzuki, J. Zhang, J. Kim,C.H. Poehlein,E.S. Antonarakis

Annals of Oncology (2022)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn